OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND

April 5, 2023

https://www.globenewswire.com/news-release/2023/04/05/2641571/35690/en/OpGen-s-Subsidiary-Curetis-Signs-Expansion-of-R-D-Collaboration-with-FIND.html

ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq:OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that it signed an amendment to its research and development (“R&D”) collaboration agreement with FIND, to expand the collaboration which was originally started in fall of 2022.

Read more at globenewswire.com

Related news for (OPGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.